Key result
DEB matches DES for major cardiovascular events in small vessels but reduces 1-year non-fatal MI.
Why the study?
Do drug-eluting balloons improve outcomes compared to drug-eluting stents in patients with small vessel coronary artery disease?
Meta-Analysis (n=1,414)
Do drug-eluting balloons improve outcomes compared to drug-eluting stents in patients with small vessel coronary artery disease?
Drug-eluting balloons demonstrate comparable long-term outcomes to drug-eluting stents in small vessel coronary artery disease, with potential benefits in reducing non-fatal MI and major bleeding.
Answers are grounded in this paper and cite their sources.
Supports DEB as alternative to DES in small vessel CAD; extends evidence with lower non-fatal MI at 1 year.
Long-term follow-up of DEB and DES use in small coronary arteries demonstrates DEBs be comparable with DESs in all outcomes at 1, 2 and 3 years of follow-up. A significant reduction was found in rates of non-fatal MI at 1 year in the DEB arm, and a reduction in major bleeding episodes at 2 years in the BASKET-SMALL 2 trial. These data highlight the potential long-term utility of novel DEBs in small coronary artery disease revascularisation.
No takes yet. Share an insight, caveat, or question.
Murphy et al. (2023) conducted a meta-analysis in Small vessel coronary artery disease (n=1,414). Drug-eluting balloons vs. Drug-eluting stents was evaluated on Major adverse cardiac events (MACE) at 1 year (OR 0.76, 95% CI 0.48-1.19, p=0.23). Drug-eluting balloons demonstrated comparable rates of major adverse cardiac events to drug-eluting stents at 1 to 3 years in small vessel coronary artery disease, with significantly reduced non-fatal MI at 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: